睿知中国医院研究地图
候选清单

南京南京大学

南京鼓楼医院

Nanjing Drum Tower Hospital

在本站收录的 53 种疾病中,这家医院列在其中 23 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

南京鼓楼医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma2 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma13 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma95 篇牵头论文牵头 2 项开放试验
  4. 胃癌Stomach cancer113 篇牵头论文牵头 3 项开放试验
  5. 骨肉瘤Osteosarcoma8 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour12 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma17 篇牵头论文
  9. 血友病 AHaemophilia A2 篇牵头论文
  10. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder0 篇牵头论文
  11. 重症肌无力Myasthenia gravis2 篇牵头论文
  12. 烟雾病Moyamoya disease7 篇牵头论文
  13. 大动脉炎Takayasu arteritis1 篇牵头论文
  14. 特发性肺纤维化Idiopathic pulmonary fibrosis31 篇牵头论文
  15. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis0 篇牵头论文
  16. 法布雷病Fabry disease0 篇牵头论文
  17. 白塞病Behçet disease0 篇牵头论文
  18. IgA 肾病IgA nephropathy3 篇牵头论文
  19. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  20. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  21. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  22. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa0 篇牵头论文
  23. 遗传性血管性水肿Hereditary angioedema1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、先天性膈疝、先天性巨结肠、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.08%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

南京有 4 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题免疫治疗
论文中的科室耳鼻喉/头颈外科肿瘤内科
牵头的论文2
  1. A bibliometric study of the nasopharyngeal cancer immunotherapy knowledge map.2024Medicine免费全文
  2. The prognostic value of before treatment neutrophil-to-lymphocyte ratio in nasopharyngeal carcinoma.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies状态不明NCT03044743牵头方(推断)I/II期2017-04 启动
PubMed 以外找到的论文(未计入)4
  1. 1372P A prospective, open and single-arm phase II clinical study of nab-paclitaxel combined with cisplatin and PD-1 inhibitor followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal2025Annals of Oncology论文
  2. Association of nutritional counselling with the severity of radiation-induced oral mucositis in patients with nasopharyngeal carcinoma: a retrospective study2024Nutrition Clinique et Métabolisme论文
  3. Beneficial role of customized intraoral stents in radiotherapy for nasopharyngeal carcinoma.2022Journal of Clinical Oncology会议摘要
  4. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.4%。

牵头论文
13
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 4420242025: 332025

南京有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因早期发现与内镜影像与人工智能
论文中的科室病理/检验科消化/肝病科普外/肝胆胰外科影像/核医学科
牵头的论文13
  1. Comparison of clinical and prognostic characteristics between superficial basaloid and conventional esophageal squamous carcinoma.2026Esophagus : official journal of the Japan Esophageal Society
  2. Epigenetically-Upregulated CD98 Shed Light on the Precancerous Diagnosis and Prognosis Prediction of Esophageal Cancer.2025Cancer science免费全文
  3. Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis.2025Frontiers in immunology免费全文
  4. Incidence of MSI-H esophageal carcinoma and related identification of genomic alterations: A multi-center real-world study.2025Human pathology
  5. Value of blood oxygenation level-dependent magnetic resonance imaging in early evaluation of the response and prognosis of esophageal squamous cell carcinoma treated with definitive chemoradiotherapy: a preliminary study.2024BMC medical imaging免费全文
  6. Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.2024Cell reports. Medicine免费全文
  7. Submucosal gland differentiation and implications in esophageal basaloid squamous cell carcinomas.2024Histology and histopathology
  8. Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids.2024Journal of translational medicine免费全文
  9. Circ_0058063 regulates cell vitality and proliferation in oesophageal squamous-cell carcinomas.2023Journal of biochemical and molecular toxicology
  10. Role of vascular endothelial growth factor in radiotherapy resistance to esophageal squamous cell carcinoma.2023Journal of cancer research and clinical oncology免费全文
  11. Association between miR-146a rs2910164, miR-196a2 rs11614913, and miR-499 rs3746444 polymorphisms and the risk of esophageal carcinoma: A case-control study.2022Cancer medicine免费全文
  12. Combined assessment of tumour cell nest size and desmoplastic reaction as an excellent prognostic predictor in oesophageal squamous cell carcinoma.2022Histopathology
  13. A Novel Deep Learning System for Diagnosing Early Esophageal Squamous Cell Carcinoma: A Multicenter Diagnostic Study.2021Clinical and translational gastroenterology免费全文
中文论文(未计入)1
  1. [Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma状态不明NCT04644250牵头方(推断)II期2020-09 启动
  2. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  3. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  4. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
PubMed 以外找到的论文(未计入)10
  1. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncology论文
  2. The combination of PD-1 inhibitor with chemotherapy ± salvage chemoradiotherapy for local primary-recurrence esophageal squamous cell carcinoma after definitive chemoradiotherapy: A prospective, multicenter, single-arm clinical study (ESO-N2025Journal of Clinical Oncology论文
  3. Tislelizumab plus short-course chemo-radiotherapy for conversion therapy of unresectable ESCC (LATE): A proof-of-concept, phase Ib trial.2025Journal of Clinical Oncology论文
  4. Effect of PLCE1-driven aerobic glycolysis through ENO1 modulation on immune evasion in esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncology会议摘要
  5. Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  6. Tagging polymorphisms in CTLA4 gene with esophageal squamous cell carcinomas: a case-control study2024Research Square预印本
  7. 172P PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment2023Immuno-Oncology Technology论文
  8. 325. THE ASSOCIATED RISK BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS OF AP1S1 AND ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN CHINESE POPULATION2022Diseases of the Esophagus论文
  9. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  10. Preoperative chemotherapy combined with PD-1 inhibitor in locally advanced operable or potentially resectable esophageal squamous cell carcinoma: A real world study.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 95 篇,占 0.6%。

牵头论文
95
2021–2025 年
牵头试验
9
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 141420212022: 141420222023: 262620232024: 202020242025: 21212025

南京有 7 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
    分期
    未注明
    开始
    2022-12
    登记号
    NCT05661786

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南京鼓楼医院南京

  2. 即将招募
    FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2026-02
    登记号
    NCT07314372

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南京鼓楼医院南京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后乙肝与肝硬化免疫与靶向药物
论文中的科室普外/肝胆胰外科病理/检验科消化/肝病科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文95
  1. Favourable Prognosis of Patients With Untreated HBeAg-Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL.2025Alimentary pharmacology & therapeutics
  2. The impact of an RNA-binding protein group on regulating the RSPO-LGR4/5-ZNRF3/RNF43 module and the immune microenvironment in hepatocellular carcinoma.2025BMC cancer免费全文
  3. BUB1 serves as a biomarker for poor prognosis in liver hepatocellular carcinoma.2025BMC immunology免费全文
  4. Villin1 predicts survival and adjuvant TACE response in hepatocellular carcinoma.2025Cancer genetics
  5. SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy.2025Cell death and differentiation免费全文
  6. RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA.2025Cell proliferation免费全文
  7. S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  8. Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues.2025Clinical and molecular hepatology免费全文
  9. Concurrent and predictive validity of the Global Leadership Initiative on Malnutrition (GLIM) criteria in patients with advanced hepatocellular carcinoma receiving systemic therapy.2025Clinical nutrition ESPEN
  10. MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  11. Bioinformatics analysis and experimental studies reveal KPNA2 as a novel biomarker of hepatocellular carcinoma progression and telomere maintenance.2025European journal of medical research免费全文
  12. Fat fraction quantification by MRI predicts diagnosis and prognosis of HBV-related steatohepatitic hepatocellular carcinoma.2025European radiology
  13. Differential HCC risk among HBV indeterminate types at baseline and by phase transition.2025Gut
  14. Pathological study of the tumor microenvironment after neoadjuvant therapy in hepatocellular carcinoma: Difference of TACE combined with antiangiogenics and immunotherapy.2025Hepatology communications免费全文
  15. Improved Hypoxic Microenvironment By Nanoformulation For Effective T Cell Therapy In Mice Model.2025International journal of nanomedicine免费全文
  16. KBTBD8/RRP15 as a potential novel therapeutic target associates with lenvatinib-inhibited progression in hepatocellular carcinoma both in vitro and in vivo.2025Journal of advanced research免费全文
  17. GSTK1 suppresses HCC aggravation via L-carnitine metabolism by PGAM5/DRP1 complex-mediated mitochondrial quality control.2025Journal of experimental & clinical cancer research : CR免费全文
  18. Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression.2025Journal of translational medicine免费全文
  19. ALKBH5 acts a tumor-suppressive biomarker and is associated with immunotherapy response in hepatocellular carcinoma.2025Scientific reports免费全文
  20. RNA nanotherapeutics for hepatocellular carcinoma treatment.2025Theranostics免费全文
  21. Apolipoprotein A1-encoding recombinant adenovirus remodels cholesterol metabolism in tumors and the tumor microenvironment to inhibit hepatocellular carcinoma.2025Translational research : the journal of laboratory and clinical medicine
  22. Composite Microparticles from Microfluidics for Chemo-/Photothermal Therapy of Hepatocellular Carcinoma.2024ACS applied materials & interfaces
  23. Letter: Association of persistently high HBsAg levels during HBeAg-seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients.2024Alimentary pharmacology & therapeutics
  24. Cascading Detection of Hydrogen Sulfide and N-Acetyltransferase 2 in Hepatocellular Carcinoma Cells Using a Two-Photon Fluorescent Probe.2024Analytical chemistry
  25. Early-life antibiotic exposure aggravate the metabolic dysfunction-associated steatotic liver disease associated hepatocellular carcinoma.2024BMC cancer免费全文
  26. N6-methyladenosine (m6A) modification in hepatocellular carcinoma.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  27. β-Catenin Activation Reprograms Ammonia Metabolism to Promote Senescence Resistance in Hepatocellular Carcinoma.2024Cancer research
  28. MVP enhances FGF21-induced ferroptosis in hepatocellular carcinoma by increasing lipid peroxidation through regulation of NOX4.2024Clinical and translational science免费全文
  29. Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial.2024ESMO open免费全文
  30. Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA.2024Emerging microbes & infections免费全文
  31. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.2024Hepatology (Baltimore, Md.)免费全文
  32. Letter to the Editor: Molecular classification based on multi-omics facilitates prognostic stratification and personalized treatment in hepatocellular carcinoma.2024Hepatology (Baltimore, Md.)
  33. Biohybrid hydrogel inhibiting β-klotho/HDAC3 axis for hepatocellular carcinoma treatment.2024International journal of biological macromolecules
  34. HOXA9 promotes proliferation, metastasis and prevents apoptosis in hepatocellular carcinoma.2024Journal of cancer research and clinical oncology免费全文
  35. Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma.2024Journal of cellular and molecular medicine免费全文
  36. DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway.2024Journal of experimental & clinical cancer research : CR免费全文
  37. Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma.2024Journal of hepatology
  38. In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response.2024Journal of translational medicine免费全文
  39. Current research insights into the role of CTLA-4 in hepatitis B virus (HBV) infection.2024Journal of viral hepatitis
  40. CT radiomics-based biomarkers can predict response to immunotherapy in hepatocellular carcinoma.2024Scientific reports免费全文
  41. Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.2024United European gastroenterology journal免费全文
  42. Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.2023Alimentary pharmacology & therapeutics
  43. HOXB13 facilitates hepatocellular carcinoma progression by activating AKT/mTOR signaling pathway.2023Annals of hepatology
  44. Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.2023BMC cancer免费全文
  45. Long noncoding RNA SNHG4 promotes the malignant progression of hepatocellular carcinoma through the miR-211-5p/CREB5 axis.2023Cancer medicine免费全文
  46. CFDP1 promotes hepatocellular carcinoma progression through activating NEDD4/PTEN/PI3K/AKT signaling pathway.2023Cancer medicine免费全文
  47. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.2023Cancer medicine免费全文
  48. FOXO1 regulates Th17 cell-mediated hepatocellular carcinoma recurrence after hepatic ischemia-reperfusion injury.2023Cell death & disease免费全文
  49. Oxoglutarate dehydrogenase-like inhibits the progression of hepatocellular carcinoma by inducing DNA damage through non-canonical function.2023Cell death and differentiation免费全文
  50. Immunotherapy for hepatocellular carcinoma.2023Clinical and experimental medicine
  51. Systematic profiling of a lipid metabolism-derived signature guides risk-stratification and therapeutic strategies in hepatocellular carcinoma.2023Clinical and translational medicine免费全文
  52. Targeting WDxR motif reprograms immune microenvironment and inhibits hepatocellular carcinoma progression.2023EMBO molecular medicine免费全文
  53. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.2023Hereditas免费全文
  54. NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-γ/p-STAT1/IRF1 pathway.2023Immunology
  55. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma.2023Immunology免费全文
  56. How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big data.2023International journal for equity in health免费全文
  57. Aberrant acetylated modification of FGF21‑KLB signaling contributes to hepatocellular carcinoma metastasis through the β‑catenin pathway.2023International journal of oncology
  58. A commentary on 'Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: a retrospective cohort study' ( Int J Surg 22023International journal of surgery (London, England)免费全文
  59. A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma.2023Investigational new drugs
  60. The XOR-IDH3α axis controls macrophage polarization in hepatocellular carcinoma.2023Journal of hepatology
  61. A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis.2023Journal of hepatology
  62. Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma.2023Journal of medical virology免费全文
  63. Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells.2023Journal of nanobiotechnology免费全文
  64. iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.2023Journal of translational medicine免费全文
  65. Liquid Biopsy in Hepatocellular Carcinoma.2023Methods in molecular biology (Clifton, N.J.)
  66. A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective study.2023PeerJ免费全文
  67. Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase.2023Virulence免费全文
  68. Contrast-enhanced CT findings-based model to predict MVI in patients with hepatocellular carcinoma.2022BMC gastroenterology免费全文
  69. Knockdown of lncRNA HAGLROS inhibits metastasis and promotes apoptosis in nephroblastoma cells by inhibition of autophagy.2022Bioengineered免费全文
  70. Association between miR-146a rs2910164, miR-196a2 rs11614913, and miR-499 rs3746444 polymorphisms and the risk of esophageal carcinoma: A case-control study.2022Cancer medicine免费全文
  71. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors.2022Cancer research
  72. An automated, rapid fluorescent immunoassay to quantify serum soluble programmed death-1 (PD-1) protein using testing-on-a-probe biosensors.2022Clinical chemistry and laboratory medicine
  73. Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis.2022Computational and mathematical methods in medicine免费全文
  74. Radiomics Analysis on Noncontrast CT for Distinguishing Hepatic Hemangioma (HH) and Hepatocellular Carcinoma (HCC).2022Contrast media & molecular imaging免费全文
  75. The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody.2022Frontiers in immunology免费全文
  76. Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis.2022Frontiers of medicine
  77. Letter to the Editor: Is HBV genotype strongly associated with HCC risk in patients with chronic hepatitis B?2022Hepatology (Baltimore, Md.)
  78. Tumor-Promoting Actions of HNRNP A1 in HCC Are Associated with Cell Cycle, Mitochondrial Dynamics, and Necroptosis.2022International journal of molecular sciences免费全文
  79. HBV Infection-Related PDZK1 Plays an Oncogenic Role by Regulating the PI3K-Akt Pathway and Fatty Acid Metabolism and Enhances Immunosuppression.2022Journal of immunology research免费全文
  80. The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription.2022Nature cancer
  81. Prognostic value of protein biomarkers in liver transplantation: A systematic review.2022Proteomics. Clinical applications
  82. Extracellular HMGB1 promotes CD44 expression in hepatocellular carcinoma via regulating miR-21.2021Aging免费全文
  83. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.2021Alimentary pharmacology & therapeutics
  84. Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B.2021Alimentary pharmacology & therapeutics
  85. Circular RNA circ_0008274 upregulates granulin to promote the progression of hepatocellular carcinoma via sponging microRNA -140-3p.2021Bioengineered免费全文
  86. Inhibition of ribosomal RNA processing 15 Homolog (RRP15), which is overexpressed in hepatocellular carcinoma, suppresses tumour growth via induction of senescence and apoptosis.2021Cancer letters
  87. PRRX1 deficiency induces mesenchymal-epithelial transition through PITX2/miR-200-dependent SLUG/CTNNB1 regulation in hepatocellular carcinoma.2021Cancer science免费全文
  88. Prognostic and predictive role of a metabolic rate-limiting enzyme signature in hepatocellular carcinoma.2021Cell proliferation免费全文
  89. Hsa-circRNA-103809 Promotes Hepatocellular Carcinoma Development via MicroRNA-1270/PLAG1 Like Zinc Finger 2 Axis.2021Digestive diseases and sciences
  90. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  91. Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report.2021Frontiers in immunology免费全文
  92. The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation.2021Immunity
  93. Asiatic Acid Encapsulated Exosomes of Hepatocellular Carcinoma Inhibit Epithelial-Mesenchymal Transition Through Transforming Growth Factor Beta/Smad Signaling Pathway.2021Journal of biomedical nanotechnology
  94. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p.2021Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  95. HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging.2021Nuclear medicine and biology
中文论文(未计入)2
  1. [New progress on diagnosis and treatment for indeterminate-phase chronic hepatitis B virus-infected patients].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Clinical features and prognostic analysis of transarterial chemoembolization combined with targeted immunotherapy in the treatment of patients with hepatitis B virus-related intermediate-and advanced-stage hepatocellular carcinoma with sec2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma即将招募NCT07314372牵头方II期2026-02 启动
  2. Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase正在招募NCT05661786牵头方2022-12 启动
  3. Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image状态不明NCT05627297牵头方2022-12 启动
  4. Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples状态不明NCT05171439牵头方II期2022-03 启动
  5. Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation状态不明NCT04595864牵头方III期2020-11 启动
  6. NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors状态不明NCT04550663牵头方I期2020-09 启动
  7. GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC状态不明NCT04121273牵头方I期2019-10 启动
  8. Clinical Characteristics of Primary Liver Cancer状态不明NCT06325267牵头方2010-01 启动
  9. The Effect of Late-evening Snacks on Patients With Primary Hepatocellular Carcinoma After Hepatectomy状态不明NCT06278701牵头方(推断)不分期2023-11 启动
  10. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  11. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  12. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)已完成NCT00617981研究中心III期2008-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 113 篇,占 1.2%。

牵头论文
113
2021–2025 年
牵头试验
7
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 262620212022: 171720222023: 252520232024: 171720242025: 23232025

南京有 8 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 10

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
    分期
    I期
    开始
    2025-12
    登记号
    NCT07298200

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:南京鼓楼医院南京

  2. 正在招募
    Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
    分期
    II期
    开始
    2024-07
    登记号
    NCT06791148

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南京鼓楼医院南京

  3. 正在招募
    Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
    分期
    II期
    开始
    2023-03
    登记号
    NCT05687357

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南京鼓楼医院;另有 2 家列出的医院为研究中心南京、太原、武汉

  4. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  5. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  6. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  7. 正在招募
    Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
    分期
    早期I期
    开始
    2025-10
    登记号
    NCT07166263

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心南京

  8. 正在招募
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    分期
    不分期
    开始
    2024-09
    登记号
    NCT06128252

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 11 家列出的医院为研究中心上海、乌鲁木齐、南京、武汉、沈阳、西安、重庆

  9. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

  10. 即将招募
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    分期
    未注明
    开始
    2026-10
    登记号
    NCT07902596

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 6 家列出的医院为研究中心上海、南京、石家庄、苏州、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物腹膜转移与晚期手术
论文中的科室消化/肝病科普外/肝胆胰外科影像/核医学科病理/检验科
牵头的论文113
  1. Dual-energy CT to evaluate the infiltration status of tumor-associated macrophage (TAM) in gastric cancer: a preliminary study.2026Abdominal radiology (New York)
  2. A nomogram model based on CT-assessed body composition parameters for predicting postoperative recurrence in advanced gastric cancer.2026Abdominal radiology (New York)
  3. Clinicopathologic and molecular mutational analysis of inflammatory fibroid polyps.2026Journal of the Formosan Medical Association = Taiwan yi zhi
  4. RBM8A confers oxaliplatin resistance in gastric cancer by maintaining EGFR mRNA stability.2026Oncogene
  5. Efficacy and safety of subserosal versus submucosal carbon nanoparticle-guided laparoscopic radical gastrectomy (DANCE-04): A randomized clinical trial.2026SurgeryRCT
  6. Dual-energy CT for predicting serosal invasion in gastric cancer and subtype analysis.2025Abdominal radiology (New York)
  7. Changes of bone, adipose, and muscle-related body compositions in gastric cancers after gastrectomy using deep learning based automatic segmentation.2025BMC gastroenterology免费全文
  8. A Multi-marker model based on serum IL-10 predicts response to conversion immunochemotherapy in gastric cancer patients: a retrospective cohort study.2025BMC gastroenterology免费全文
  9. Inflammatory and nutritional markers predict response and prognosis of patients with locally advanced gastric cancer receiving neoadjuvant immunochemotherapy.2025BMC gastroenterology免费全文
  10. Clinical Characteristics, Prognostic Factors and Therapeutic Strategies in Gastric Cancer Patients With Bone Metastasis: A Retrospective Analysis.2025Cancer medicine免费全文
  11. Identification of AXL as a novel positive regulator of lipid raft in gastric cancer.2025Cellular signalling
  12. Expression Patterns of Immune Checkpoint Molecules and Their Clinical Values in Gastric Neuroendocrine Neoplasms.2025Clinical and translational gastroenterology免费全文
  13. Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer.2025Current oncology (Toronto, Ont.)免费全文
  14. Circulating PD-1+ effector memory T cells predict anti-PD-1 efficacy in advanced gastric cancer.2025Frontiers in immunology免费全文
  15. A rapid ex vivo co-culture of memory-like NK and activated T cells enhances anti-tumor response in gastric cancer.2025International immunopharmacology
  16. Novel tetrameric bispecific KK-LC-1×CD16A-armed memory-like NK cells enhance antitumor efficacy in gastric cancer.2025Journal for immunotherapy of cancer免费全文
  17. Analysis of clinicopathologic characteristics and risk factors for missed diagnosis in synchronous multiple early gastric cancer.2025Journal of cancer research and clinical oncology免费全文
  18. Preoperative Prediction of Sarcopenia in Patients Scheduled for Gastric and Colorectal Cancer Surgery.2025Journal of gastrointestinal cancer
  19. Effects of perioperative ω-3 fish oil fat emulsion on postoperative gastric emptying function following Roux-en-Y reconstruction for gastric cancer.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  20. Long-term outcomes of additional surgery vs. observation after noncurative endoscopic submucosal dissection for early gastric cancer and application value of the eCura scoring system: a propensity score-matched study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  21. Non-canonical small noncoding RNAs in the plasma extracellular vesicles as novel biomarkers in gastric cancer.2025Journal of hematology & oncology免费全文
  22. Investigating the role of intratumoral Streptococcus mitis in gastric cancer progression: insights into tumor microenvironment.2025Journal of translational medicine免费全文
  23. NNMT-mediated N6-methyladenosine modification of NR4A3 mRNA facilitates lymphatic metastasis of gastric adenocarcinoma.2025Oncogene
  24. The strategy of vitamin supplementation in Chinese patients with gastric cancer after gastrectomy: a prospective cohort study.2025Scientific reports免费全文
  25. Impact of distal or pylorus preserving gastrectomy on postoperative quality of life in T1 stage middle third gastric cancer patients.2025Scientific reports免费全文
  26. DRAM1 enhances the proliferation and metastasis of gastric cancer through the PI3K/AKT/mTOR signaling pathway and energy metabolism.2025Scientific reports免费全文
  27. Machine learning-assisted washing-free detection of extracellular vesicles by target recycling amplification based fluorescent aptasensor for accurate diagnosis of gastric cancer.2025Talanta
  28. Pancreatic atrophy after gastric cancer surgery: influencing factors and effects on BMI and quality of life.2025World journal of surgical oncology免费全文
  29. Epstein-Barr virus positive gastric cancer: the pathological basis of CT findings and radiomics models prediction.2024Abdominal radiology (New York)
  30. Enhanced Photodynamic Therapy Synergizing with Inhibition of Tumor Neutrophil Ferroptosis Boosts Anti-PD-1 Therapy of Gastric Cancer.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  31. Red ginseng polysaccharide promotes ferroptosis in gastric cancer cells by inhibiting PI3K/Akt pathway through down-regulation of AQP3.2024Cancer biology & therapy免费全文
  32. Cross-talk between gastric cancer and hepatic stellate cells promotes invadopodia formation during liver metastasis.2024Cancer science免费全文
  33. Sotos Syndrome with NSDI Gene Mutations and Li-Fraumeni Syndrome with TP53 Gene Mutations in a Patient with Multiple Gastric Signet-Ring Cell Carcinomas.2024Digestive diseases and sciences
  34. Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer.2024EMBO molecular medicine免费全文
  35. Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer.2024EMBO molecular medicine免费全文
  36. Thirdhand smoke exposure promotes gastric tumor development in mouse and human.2024Environment international
  37. Case report: A case of advanced gastric cancer with multiple skin metastases, with significant relief from immunotherapy.2024Frontiers in immunology免费全文
  38. Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design.2024Human vaccines & immunotherapeutics免费全文
  39. Gastric Ganglioneuroblastoma in an Elderly man: A Case Report and Literature Review.2024International journal of surgical pathology
  40. Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world.2024Journal of cancer research and clinical oncology免费全文
  41. NTRK gene alterations were enriched in hepatoid or enteroblastic differentiation type of gastric cancer.2024Journal of clinical pathology免费全文
  42. CircUSP1 as a novel marker promotes gastric cancer progression via stabilizing HuR to upregulate USP1 and Vimentin.2024Oncogene免费全文
  43. Helicobacter pylori infection increases risk of bleeding during endoscopic submucosal dissection for early gastric cancer.2024Surgical endoscopy
  44. Risk factors of missed early gastric cancer in endoscopic resected population: a retrospective, case-control study.2024Surgical endoscopy
  45. A Superficial Spreading Type of Early Gastric Cancer Arising in Autoimmune Gastritis.2024The American journal of gastroenterology
  46. The potential effect and mechanism of Saikosaponin A against gastric cancer.2023BMC complementary medicine and therapies免费全文
  47. Risk factors of additional surgery after non-curative endoscopic submucosal dissection for early gastric cancer.2023BMC gastroenterology免费全文
  48. Comparison of clinical and pathological features between early-stage gastric-type and intestinal-type differentiated adenocarcinoma: a retrospective study.2023BMC gastroenterology免费全文
  49. Comparison of clinical outcomes and prognosis between surgery and endoscopic submucosal dissection in patients with synchronous multifocal early gastric cancer.2023BMC surgery免费全文
  50. CircRNA CDR1as: a novel diagnostic and prognostic biomarker for gastric cancer.2023Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  51. Necroptosis Related Genes Predict Prognosis and Therapeutic Potential in Gastric Cancer.2023Biomolecules免费全文
  52. Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer.2023British journal of cancer免费全文
  53. Genetic risk, metabolic syndrome, and gastrointestinal cancer risk: A prospective cohort study.2023Cancer medicine免费全文
  54. Real-world clinical outcomes of the combination of anti-PD-1 antibody, trastuzumab, and chemotherapy for HER2-positive gastric/gastroesophageal junction cancer.2023Cancer medicine免费全文
  55. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.2023Cancer science免费全文
  56. Comparison of Modified Cap-Assisted Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection in Treating Intraluminal Gastric Gastrointestinal Stromal Tumor (≤20 mm).2023Clinical and translational gastroenterology免费全文
  57. Comparison of Safety and Outcomes between Endoscopic and Surgical Resections of Intermediate-Risk Primary Gastric Gastrointestinal Stromal Tumors.2023Digestive diseases (Basel, Switzerland)
  58. Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case-control study.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  59. NNMT enriches for AQP5+ cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma.2023Gut
  60. Gastrointestinal: A case of type 1 gastric neuroendocrine tumor with multiple endocrine neoplasia type 1.2023Journal of gastroenterology and hepatology
  61. Subserosal Indocyanine Green Plus Submucosal Carbon Nanoparticle Navigated Laparoscopic Gastrectomy (DANCE-01): a Cohort Study.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  62. Determination of polyamines in urine via electrospun nanofibers-based solid-phase extraction coupled with GC-MS and application to gastric cancer patients.2023Journal of separation science
  63. Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial.2023Nature communications免费全文
  64. ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways.2023Neoplasia (New York, N.Y.)免费全文
  65. H19 encourages aerobic glycolysis and cell growth in gastric cancer cells through the axis of microRNA-19a-3p and phosphoglycerate kinase 1.2023Scientific reports免费全文
  66. Mixed Histologic Type is a Risk Factor for Lymph Node Metastasis in Submucosal Invasive Early Gastric Cancer.2023The Journal of surgical research
  67. Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.2023The oncologist免费全文
  68. Dual tracer navigation for lymph node dissection in laparoscopic radical gastrectomy (DANCE trial): a protocol for a prospective, randomized clinical trial.2023Trials免费全文
  69. Establishment and verification of prediction model of occult peritoneal metastasis in advanced gastric cancer.2023World journal of surgical oncology免费全文
  70. Prognostic analysis of 2-5 cm diameter gastric stromal tumors with exogenous or endogenous growth.2023World journal of surgical oncology免费全文
  71. Clinicopathological features and CT findings of papillary gastric adenocarcinoma.2022Abdominal radiology (New York)
  72. APAF1-Binding Long Noncoding RNA Promotes Tumor Growth and Multidrug Resistance in Gastric Cancer by Blocking Apoptosome Assembly.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  73. Application of preoperative CT texture analysis in papillary gastric adenocarcinoma.2022BMC cancer免费全文
  74. Integrative analysis of the proteome and transcriptome in gastric cancer identified LRP1B as a potential biomarker.2022Biomarkers in medicine
  75. A novel active mitochondrion-selective fluorescent probe for the NIR fluorescence imaging and targeted photodynamic therapy of gastric cancer.2022Biomaterials science
  76. DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer.2022Cancer immunology research
  77. A Retrospective Cohort Study of Factors Influencing Lymph Node Metastasis in Patients With Early Gastric Papillary Adenocarcinoma.2022Clinical and translational gastroenterology免费全文
  78. An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer.2022European journal of medicinal chemistry
  79. Associations of Education Level With Survival Outcomes and Treatment Receipt in Patients With Gastric Adenocarcinoma.2022Frontiers in public health免费全文
  80. Predictive Factors for Acute Postoperative Pain After Open Radical Gastrectomy for Gastric Cancer.2022Frontiers in public health免费全文
  81. Comparison of endoscopic full-thickness resection and cap-assisted endoscopic full-thickness resection in the treatment of small (≤1.5 cm) gastric GI stromal tumors.2022Gastrointestinal endoscopy
  82. Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers.2022Gut and liver免费全文
  83. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.2022Journal of cancer research and clinical oncology免费全文
  84. C-Reactive Protein/Albumin Ratio on the First Day after Surgery Predicts Short-Term Complications of Gastrectomy for Gastric Cancer.2022Nutrition and cancer
  85. Development and validation of multivariate models integrating preoperative clinicopathological and radiographic findings to predict HER2 status in gastric cancer.2022Scientific reports免费全文
  86. A deep learning-based model improves diagnosis of early gastric cancer under narrow band imaging endoscopy.2022Surgical endoscopy
  87. Comparison of short-term outcomes between robotic-assisted and laparoscopic gastrectomy guided by carbon nanoparticle suspension injection in gastric cancer.2022World journal of surgical oncology免费全文
  88. Preoperative T2-weighted MR imaging texture analysis of gastric cancer: prediction of TNM stages.2021Abdominal radiology (New York)
  89. Development and Validation of Multivariate Models Integrating Preoperative Clinicopathological Parameters and Radiographic Findings Based on Late Arterial Phase CT Images for Predicting Lymph Node Metastasis in Gastric Cancer.2021Academic radiology
  90. Naturally occurring aesculetin coumarin exerts antiproliferative effects in gastric cancer cells mediated via apoptotic cell death, cell cycle arrest and targeting PI3K/AKT/M-TOR signalling pathway.2021Acta biochimica Polonica
  91. ASO Author Reflections: Comparison of Three Lymph Node Staging Systems for Prognostic Evaluation of Resected Gastric Adenocarcinoma.2021Annals of surgical oncology
  92. Prediction of serosal invasion in gastric cancer: development and validation of multivariate models integrating preoperative clinicopathological features and radiographic findings based on late arterial phase CT images.2021BMC cancer免费全文
  93. Clinicopathological significance of HSP70 expression in gastric cancer: a systematic review and meta-analysis.2021BMC gastroenterology免费全文
  94. Clinical outcomes of early gastric cardiac cancer treated with endoscopic submucosal dissection in patients with different indications.2021BMC gastroenterology免费全文
  95. Controlling Nutritional Status (CONUT) score as a predictive marker for short-term complications following gastrectomy of gastric cancer: a retrospective study.2021BMC gastroenterology免费全文
  96. Risk factors for lymph node metastasis in gastric neuroendocrine tumor: a retrospective study.2021BMC surgery免费全文
  97. UBE2C mRNA expression controlled by miR-300 and HuR determines its oncogenic role in gastric cancer.2021Biochemical and biophysical research communications
  98. Circular RNAs emerge as important regulators with great potential for clinical application in gastric cancer.2021Biomarkers in medicine
  99. Identification of a peptide binding to cancer antigen Kita-kyushu lung cancer antigen 1 from a phage-display library.2021Cancer science免费全文
  100. Tenascin-c knockdown suppresses vasculogenic mimicry of gastric cancer by inhibiting ERK- triggered EMT.2021Cell death & disease免费全文
  101. Lipophilic recombinant-protein insertion endows lymphocytes with enhanced targeting-infiltration ability in EGFR positive cancer.2021Cellular immunology
  102. Apolipoprotein C-II induces EMT to promote gastric cancer peritoneal metastasis via PI3K/AKT/mTOR pathway.2021Clinical and translational medicine免费全文
  103. Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen?2021Clinical nuclear medicine
  104. OSI-027 Alleviates Oxaliplatin Chemoresistance in Gastric Cancer Cells by Suppressing P-gp Induction.2021Current molecular medicine
  105. A deep learning-based system for identifying differentiation status and delineating the margins of early gastric cancer in magnifying narrow-band imaging endoscopy.2021Endoscopy
  106. Gastric poorly cohesive carcinoma: differentiation from tubular adenocarcinoma using nomograms based on CT findings in the 40 s late arterial phase.2021European radiology
  107. RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  108. Integrated clinicopathological and immunohistochemical analysis of gastric adenocarcinoma with hepatoid differentiation: an exploration of histogenesis, molecular characteristics, and prognostic markers.2021Human pathology
  109. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.2021Journal for immunotherapy of cancer免费全文
  110. FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma.2021Journal of translational medicine免费全文
  111. The Addition of ω-3 Fish Oil Fat Emulsion to Parenteral Nutrition Reduces Short-Term Complications after Laparoscopic Surgery for Gastric Cancer.2021Nutrition and cancer
  112. Anoikis resistant gastric cancer cells promote angiogenesis and peritoneal metastasis through C/EBPβ-mediated PDGFB autocrine and paracrine signaling.2021Oncogene
  113. The short-term and long-term outcomes of indocyanine green tracer-guided laparoscopic radical gastrectomy in patients with gastric cancer.2021World journal of surgical oncology免费全文
中文论文(未计入)8
  1. [Consistency of claudin 18.2 expression with antibodies of different clones in gastric adenocarcinoma].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Application of PMS2 and MSH6 double-antibody detection in screening of mismatch repair deficient tumors].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Exploration of biomarkers for the efficacy of anti-PD-1 immunotherapy in patients with gastric cancer peritoneal metastasis].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Clinicopathological and molecular features of two cases of early gastric adenocarcinoma with enteroblastoid differentiation treated by endoscopic submucosal dissection].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Clinicopathological features of gastric carcinomas with NTRK-rearrangement/amplification: report of four cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  6. [Comparison of quality-of-life after proximal gastrectomy with double tract reconstruction versus gastric tube reconstruction in patients with proximal gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Skip metastasis at the esophageal resection margin in radical gastrectomy: clinical characteristics of 30 cases].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Accurate diagnosis and individualized treatment of advanced gastric cancer: pathological detection of biomarkers based on cancer tissue samples].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)27
  1. Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer正在招募NCT06791148牵头方II期2024-07 启动
  2. Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma正在招募NCT05687357牵头方II期2023-03 启动
  3. Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients状态不明NCT02381847牵头方III期2015-01 启动
  4. Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC状态不明NCT03061058牵头方III期2013-04 启动
  5. Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer正在招募NCT07298200牵头方(推断)I期2025-12 启动
  6. Pulsed Low Dose Rate Radiation Therapy for Gastric Cancer Patients With Peritoneal Metastasis状态不明NCT03061162牵头方(推断)不分期2017-03 启动
  7. PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies状态不明NCT03044743牵头方(推断)I/II期2017-04 启动
  8. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  9. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  10. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma即将招募NCT07902596研究中心2026-10 启动
  11. Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer正在招募NCT07166263研究中心早期I期2025-10 启动
  12. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  13. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  14. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer正在招募NCT06128252研究中心不分期2024-09 启动
  15. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma已终止NCT06206278研究中心II期2023-10 启动
  16. A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer状态不明NCT05395780研究中心II期2022-06 启动
  17. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors已完成NCT05253053研究中心I/II期2022-04 启动
  18. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  19. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  20. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  21. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations状态不明NCT05019794研究中心II期2020-05 启动
  22. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  23. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  24. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  25. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer已完成NCT03427814研究中心II期2018-07 启动
  26. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  27. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study状态不明NCT03121729研究中心不分期2017-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.4%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 3320242025: 332025

南京有 25 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Osteosarcoma Cell-Derived Migrasomes Promote Macrophage M2 Polarization to Aggravate Osteosarcoma Proliferation and Metastasis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Identification of effective anti-osteosarcoma agents via screening of an in-house NQO1-targeted compound library.2025Bioorganic & medicinal chemistry
  3. Intelligent drug codelivery platform for immune microenvironment reconstruction and immunochemotherapy in osteosarcoma treatment.2025European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  4. Doxorubicin-Loaded Microalgal Delivery System for Combined Chemotherapy and Enhanced Photodynamic Therapy of Osteosarcoma.2024ACS applied materials & interfaces
  5. Long noncoding RNA TUG1 promotes malignant progression of osteosarcoma by enhancing ZBTB7C expression.2024Biomedical journal
  6. C-C Motif Chemokine Ligand 5 (CCL5): A Potential Biomarker and Immunotherapy Target for Osteosarcoma.2024Current cancer drug targets
  7. USP48 alleviates bone cancer pain and regulates MrgC stabilization in spinal cord neurons of male mice.2023European journal of pain (London, England)
  8. ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression.2023Translational research : the journal of laboratory and clinical medicine
早期论文(2016–2020 年)7
  1. The therapeutic value of the SphK1-targeting microRNA-3677 in human osteosarcoma cells.2020Aging
  2. Clinical Outcome of Free Vascularized Fibula Graft in the Surgical Treatment of Extremity Osteosarcoma.2020Orthopaedic surgery
  3. Evaluation of sleep quality in adolescent patients with osteosarcoma using Pittsburgh Sleep Quality Index.2019European journal of cancer care
  4. Genetic Variant of NFIB is Associated With the Metastasis of Osteosarcoma in Chinese Population.2019Technology in cancer research & treatment
  5. CEP55 promotes the proliferation and invasion of tumour cells via the AKT signalling pathway in osteosarcoma.2018Carcinogenesis
  6. Reconstruction of bone defect with allograft and retrograde intramedullary nail for distal tibia osteosarcoma.2018Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons
  7. Positive feedback regulation between microRNA-132 and CREB in spinal cord contributes to bone cancer pain in mice.2016European journal of pain (London, England)

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 12 篇,占 2.3%。

牵头论文
12
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 8820232024: 1120242025: 112025

南京有 11 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科普外/肝胆胰外科病理/检验科临床试验/研究机构
牵头的论文12
  1. Huaier inhibits the proliferation and migration of gastrointestinal stromal tumors by regulating the JAK2 / STAT3 signaling pathway.2025Journal of ethnopharmacology
  2. Clinical characteristics and prognostic analysis of postoperative recurrence or metastasis of low-risk gastrointestinal stromal tumors.2024World journal of surgical oncology
  3. Controlling Nutritional Status (CONUT) score as a prognostic marker for gastrointestinal stromal tumours.2023ANZ journal of surgery
  4. Prognostic significance of serum CA125 in the overall management for patients with gastrointestinal stromal tumors.2023BMC gastroenterology
  5. Comparison of Modified Cap-Assisted Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection in Treating Intraluminal Gastric Gastrointestinal Stromal Tumor (≤20 mm).2023Clinical and translational gastroenterology免费全文
  6. Comparison of Safety and Outcomes between Endoscopic and Surgical Resections of Intermediate-Risk Primary Gastric Gastrointestinal Stromal Tumors.2023Digestive diseases (Basel, Switzerland)
  7. Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case-control study.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  8. KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients.2023Journal of gastroenterology and hepatology
  9. Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2.2023Journal of translational medicine
  10. Prognostic analysis of 2-5 cm diameter gastric stromal tumors with exogenous or endogenous growth.2023World journal of surgical oncology免费全文
  11. Comparison of endoscopic full-thickness resection and cap-assisted endoscopic full-thickness resection in the treatment of small (≤1.5 cm) gastric GI stromal tumors.2022Gastrointestinal endoscopy
  12. Prognostic value of Onodera's nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors.2021World journal of surgical oncology
中文论文(未计入)1
  1. [Esophageal gastrointestinal stromal tumor with MKRN1::BRAF gene fusion: report of a case].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
早期论文(2016–2020 年)5
  1. Treatment options for giant gastrointestinal stromal tumours and related prognosis: a single-centre retrospective study.2020ANZ journal of surgery
  2. Retrospective Comparison of Endoscopic Full-Thickness Versus Laparoscopic or Surgical Resection of Small (≤ 5 cm) Gastric Gastrointestinal Stromal Tumors.2020Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  3. Comparative clinical features and short-term outcomes of gastric and small intestinal gastrointestinal stromal tumours: a retrospective study.2019Scientific reports
  4. Texture analysis of CT images in predicting malignancy risk of gastrointestinal stromal tumours.2018Clinical radiology
  5. The fourth space surgery: endoscopic subserosal dissection for upper gastrointestinal subepithelial tumors originating from the muscularis propria layer.2018Surgical endoscopy
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study on Integrated Nursing Strategy for Patients With Gastrointestinal Stromal Tumors After Targeted Therapy状态不明NCT05665868牵头方不分期2022-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南京有 10 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
牵头的论文1
  1. Gastric Ganglioneuroblastoma in an Elderly man: A Case Report and Literature Review.2024International journal of surgical pathology

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 17 篇,占 1.0%。

牵头论文
17
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
10
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 5520222023: 2220232024: 2220242025: 222025

南京有 7 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 10

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-02
    登记号
    NCT07258511

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安

  2. 正在招募
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春

  3. 正在招募
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07555938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛

  4. 正在招募
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    分期
    I期
    开始
    2025-12
    登记号
    NCT07179679

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、南京、南充、南昌、广州、承德、苏州、西安、重庆

  5. 正在招募
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-05
    登记号
    NCT06375044

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、广州、杭州、福州、郑州

  6. 正在招募
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    分期
    IV期
    开始
    2022-03
    登记号
    NCT05201781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安

  7. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  8. 正在招募
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    分期
    III期
    开始
    2022-11
    登记号
    NCT05623020

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春

  9. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

  10. 即将招募
    A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
    分期
    I期
    开始
    2022-04
    登记号
    NCT05181501

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心南京、合肥、常州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层复发与耐药联合用药
论文中的科室临床试验/研究机构肿瘤内科
牵头的论文17
  1. ZMYND8 Reads H3K36me2 to Activate CEBPE Transcription and Suppress Multiple Myeloma Progression through the Inhibition of Adaptive UPR Pathways.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Identifying potential prognosis markers in relapsed multiple myeloma via integrated bioinformatics analysis and biological experiments.2025Current research in translational medicine
  3. Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients.2024Hematology (Amsterdam, Netherlands)
  4. Leveraging diverse cellular stress patterns for predicting clinical outcomes and therapeutic responses in patients with multiple myeloma.2024Journal of cellular and molecular medicine免费全文
  5. A novel prognostic model based on pyroptosis-related genes for multiple myeloma.2023BMC medical genomics免费全文
  6. N6-methyladenosine regulators are potential prognostic biomarkers for multiple myeloma.2023IUBMB life免费全文
  7. CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation.2022Aging免费全文
  8. Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma.2022Clinical and experimental pharmacology & physiology免费全文
  9. Comparison of clinical features of multiple myeloma with paraosseous and extraosseous plasmacytoma in the era of novel drugs: a systemic review and meta-analysis.2022Expert review of hematology
  10. Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification.2022Frontiers in public health免费全文
  11. Formosanin C induces autophagy-mediated apoptosis in multiple myeloma cells through the PI3K/AKT/mTOR signaling pathway.2022Hematology (Amsterdam, Netherlands)
  12. Licochalcone A suppresses Sp1 expression with potential anti-myeloma activity.2021Cancer communications (London, England)免费全文
  13. Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma.2021Cancer medicine免费全文
  14. DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination.2021Carcinogenesis
  15. PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.2021Cell death & disease免费全文
  16. Gene signatures and prognostic values of m6A-related genes in multiple myeloma.2021Current research in translational medicine
  17. Metabolic markers for diagnosis and risk-prediction of multiple myeloma.2021Life sciences
中文论文(未计入)1
  1. [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
  1. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma正在招募NCT07555938研究中心III期2026-06 启动
  2. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07518186研究中心III期2026-05 启动
  3. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07258511研究中心III期2026-02 启动
  4. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors正在招募NCT07179679研究中心I期2025-12 启动
  5. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06375044研究中心I期2024-05 启动
  6. A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)即将招募NCT05181501研究中心I期2022-04 启动
  7. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant正在招募NCT05623020研究中心III期2022-11 启动
  8. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel正在招募NCT05201781研究中心IV期2022-03 启动
  9. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  10. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  11. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  12. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  13. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  14. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  15. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.已完成NCT05228470研究中心II期2021-12 启动
  16. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)状态不明NCT05066646研究中心I/II期2020-04 启动
  17. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已终止NCT03758417研究中心II期2019-01 启动
  18. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  19. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  20. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma已终止NCT03215030研究中心I/II期2017-10 启动
  21. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  22. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

南京有 7 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    分期
    III期
    开始
    2025-03
    登记号
    NCT06833983

    年龄 18 岁 至 65 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科
牵头的论文2
  1. The Role of Clot Waveform Analysis and Related Parameters in the Diagnosis and Treatment of Hemophilia A.2024Thrombosis and haemostasis
  2. What can we expect for adolescents and adults with haemophilia switched to low-dose prophylaxis from episodic treatment for over 3 years? A real-world snapshot in China.2021Haemophilia : the official journal of the World Federation of Hemophilia
中文论文(未计入)1
  1. [Analysis of the effects of low/intermediate dose of coagulation factor Ⅷ on 30 adult patients with severe hemophilia A in a single center].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
早期论文(2016–2020 年)1
  1. Age-related severity and distribution of haemophilic arthropathy of the knee, ankle and elbow among Chinese patients with haemophilia.2020Haemophilia : the official journal of the World Federation of Hemophilia
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A正在招募NCT06833983研究中心III期2025-03 启动
  2. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动
  3. A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A已完成NCT04565236研究中心IV期2020-09 启动
  4. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.状态不明NCT04061109研究中心III期2019-05 启动
  5. ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)已完成NCT02078427研究中心2011-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年没有牵头视神经脊髓炎谱系疾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders进行中,不再招募NCT06044350研究中心II期2023-08 启动
  2. Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica状态不明NCT01364246研究中心I/II期2010-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

南京有 2 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题胸腺与胸腺切除生物制剂与补体抑制剂

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 7 篇,占 2.0%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 1120242025: 332025

南京有 3 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流血管重建手术儿童
论文中的科室影像/核医学科神经外科神经内科
牵头的论文7
  1. Long-term clinical and radiological outcomes of extracranial-intracranial bypass in hemorrhagic patients with Moyamoya disease: A single-center observational study of 45 cases.2025Neurosurgical review
  2. The intraoperative hemodynamic and clinical research of three direct bypasses in moyamoya disease a prospective cohort of 98 cases.2025Scientific reports免费全文
  3. Enhanced blood vessel visualization and accelerated image acquisition using spiral magnetic resonance angiography in moyamoya disease: a comparative study with Cartesian magnetic resonance angiograhy.2025The British journal of radiology
  4. GM-CSF Promotes the Development of Dysfunctional Vascular Networks in Moyamoya Disease.2024Neuroscience bulletin免费全文
  5. Risk Factors for Cerebrovascular Events in Moyamoya Angiopathy Using 4D Flow MRI: A Pilot Study.2023Journal of magnetic resonance imaging : JMRI
  6. Association of contrast enhancement of proximal internal carotid artery wall and champagne bottle neck sign with ipsilateral stroke in moyamoya disease patients.2022European journal of radiology
  7. Recurrent hemorrhage risk associated with medial target medullary artery anastomosis from the periventricular collateral vessel in adult patients with moyamoya disease.2021BMC neurology免费全文
中文论文(未计入)1
  1. [Correlation analysis between decreased cerebral perfusion measured from arterial spin labeling and cerebrovascular events in patients with bilateral moyamoya angiography].2021Zhonghua yi xue za zhi
PubMed 以外找到的论文(未计入)1
  1. Collateral Predictors of Neovascularization After Indirect Revascularization in Adult Patients with Moyamoya Disease: A Single-Center Retrospective Study2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

南京有 2 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科
牵头的论文1
  1. Factors associated with event-free survival in Chinese patients with Takayasu's arteritis.2021Clinical rheumatology
早期论文(2016–2020 年)2
  1. Clinical Experience of Aortic Valve Surgery in Patients With Aortitis Disease.2019The heart surgery forum
  2. [Unilateral pleural effusion as first manifestation in Takayasu arteritis: a case report and review of literature].2016Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 31 篇,占 3.1%。

牵头论文
31
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 4420222023: 5520232024: 9920242025: 882025

南京有 15 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

  2. 正在招募
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    分期
    II期
    开始
    2025-11
    登记号
    NCT07121413

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、南京、南昌、呼和浩特、天津、广州、徐州、成都、杭州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科风湿免疫科
牵头的论文31
  1. Integrin/CD44-targeted liposomes remodel the pulmonary microenvironment to alleviate acute exacerbation of pulmonary fibrosis.2026Journal of controlled release : official journal of the Controlled Release Society
  2. Targeting Senescent Alveolar Type 2 Cells with a Gene-Editable FePt Dual-Atom Catalyst for Mitigating Idiopathic Pulmonary Fibrosis.2025ACS nano
  3. Histone methyltransferase KMT2A promotes pulmonary fibrogenesis via targeting pro-fibrotic factor PU.1 in fibroblasts.2025Clinical and translational medicine
  4. Nomogram model using serum Club cell secretory protein 16 to predict prognosis and acute exacerbation in patients with idiopathic pulmonary fibrosis.2025European journal of medical research
  5. Isorhapontigenin alleviates pulmonary fibrosis by inhibiting oxidative stress-induced senescence via STAT3/PRDX2 signals in alveolar epithelial cells.2025International immunopharmacology
  6. Air pollution exposure modes, smoking and genetic risk with chronic respiratory diseases: a prospective study.2025NPJ primary care respiratory medicine
  7. Serum cholesterol levels predict the survival in patients with idiopathic pulmonary fibrosis: A long-term follow up study.2025Respiratory medicine
  8. The potential lipid biomarker 5-HETE for acute exacerbation identified by metabolomics in patients with idiopathic pulmonary fibrosis.2025Respirology (Carlton, Vic.)
  9. Identifying TNFSF4low-MSCs superiorly treating idiopathic pulmonary fibrosis through Tregs differentiation modulation.2025Stem cell research & therapy
  10. Novel 3D-based deep learning for classification of acute exacerbation of idiopathic pulmonary fibrosis using high-resolution CT.2024BMJ open respiratory research
  11. Gene expression profile analysis of severe influenza-based modulation of idiopathic pulmonary fibrosis.2024European journal of medical research
  12. HE4-based nomogram for predicting overall survival in patients with idiopathic pulmonary fibrosis: construction and validation.2024European journal of medical research
  13. The gene expression of CALD1, CDH2, and POSTN in fibroblast are related to idiopathic pulmonary fibrosis.2024Frontiers in immunology
  14. PGC-1α regulates endoplasmic reticulum stress in IPF-derived fibroblasts.2024International immunopharmacology
  15. Shared biomarkers and mechanisms in idiopathic pulmonary fibrosis and non-small cell lung cancer.2024International immunopharmacology
  16. Exosomal circRNAs in the plasma serve as novel biomarkers for IPF diagnosis and progression prediction.2024Journal of translational medicine
  17. Senescent lung-resident mesenchymal stem cells drive pulmonary fibrogenesis through FGF-4/FOXM1 axis.2024Stem cell research & therapy
  18. Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.2024The European respiratory journal
  19. Elevated serum mitochondrial DNA levels were associated with the progression and mortality in idiopathic pulmonary fibrosis.2023International immunopharmacology
  20. Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy.2023Journal of molecular medicine (Berlin, Germany)
  21. Assessment and Management of Cough in Idiopathic Pulmonary Fibrosis: A Narrative Review.2023Lung
  22. Diagnostic finding on high-resolution computed tomography (HRCT) predicts a good response to pirfenidone in patients with idiopathic pulmonary fibrosis.2023Medicine
  23. Animal models of acute exacerbation of pulmonary fibrosis.2023Respiratory research
  24. KLF4 regulates TERT expression in alveolar epithelial cells in pulmonary fibrosis.2022Cell death & disease
  25. Elevated Expression of Growth Differentiation Factor-15 Is Associated With Acute Exacerbation of Idiopathic Pulmonary Fibrosis.2022Frontiers in immunology
  26. Prognostic Role of NLR, PLR and MHR in Patients With Idiopathic Pulmonary Fibrosis.2022Frontiers in immunology
  27. Human epididymis protein 4 is associated with severity and poor prognosis of connective tissue disease-associated interstitial lung disease with usual interstitial pneumonia pattern.2022International immunopharmacology
  28. Idiopathic pulmonary fibrosis associated with circulating autoantibodies: a Chinese cohort of a long-term follow-up study.2021Chinese medical journal
  29. Construction of potential idiopathic pulmonary fibrosis related microRNA and messenger RNA regulatory network.2021Chinese medical journal
  30. Protective function of interleukin-22 in pulmonary fibrosis.2021Clinical and translational medicine
  31. Idiopathic pleuroparenchymal fibroelastosis confirmed by pathology: a case report.2021The Journal of international medical research
早期论文(2016–2020 年)22
  1. Prognostic Value of Serum Osteopontin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.2020BioMed research international
  2. Correlation between serum bilirubin levels and the severity as well as the prognosis of idiopathic pulmonary fibrosis.2020Chronic respiratory disease
  3. Association of serum macrophage-mannose receptor CD206 with mortality in idiopathic pulmonary fibrosis.2020International immunopharmacology
  4. Associations of Serological Biomarkers of sICAM-1, IL-1β, MIF, and su-PAR with 3-Month Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.2020Mediators of inflammation
  5. Incidence and impact of extra-pulmonary organ failures on hospital mortality in acute exacerbation of idiopathic pulmonary fibrosis.2020Scientific reports
  6. Epithelial cell senescence induces pulmonary fibrosis through Nanog-mediated fibroblast activation.2019Aging
  7. PTEN loss regulates alveolar epithelial cell senescence in pulmonary fibrosis depending on Akt activation.2019Aging
  8. Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF-κB activation.2019Aging cell
  9. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study.2019BMC pulmonary medicine
  10. Acute exacerbation of idiopathic pulmonary fibrosis: usual interstitial pneumonitis vs. possible usual interstitial pneumonitis pattern.2019Chinese medical journal
  11. A long-term retrospective study of patients with biopsy-proven cryptogenic organizing pneumonia.2019Chronic respiratory disease
  12. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.2019Histopathology
  13. Prognostic value of IFN-γ, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis.2019International immunopharmacology
  14. The relationship between MUC5B promoter, TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort.2019Scientific reports
  15. Clinical features, risk factors, and outcomes of patients with interstitial pneumonia with autoimmune features: a population-based study.2018Clinical rheumatology
  16. M2 macrophages induce EMT through the TGF-β/Smad2 signaling pathway.2017Cell biology international
  17. Radial Probe Endobronchial Ultrasound-guided Lung Biopsy for Histopathological Diagnosis of Cryptogenic Organizing Pneumonia.2017Chinese medical journal
  18. [Pulmonary intravascular large B-cell lymphomamanifesting as interstitial pneumonias: report of 2 cases and review of literature].2017Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  19. Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis.2016Diagnostic pathology
  20. Plasma Leptin Is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.2016Mediators of inflammation
  21. Elevated sL1-CAM levels in BALF and serum of IPF patients.2016Respirology (Carlton, Vic.)
  22. Telomere length and survival in IPF patients - Reply.2016Respirology (Carlton, Vic.)
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis正在招募NCT07121413研究中心II期2025-11 启动
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动
  5. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis已终止NCT06360094研究中心II期2024-08 启动
  6. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06335303研究中心II期2024-09 启动
  7. A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects已完成NCT05895565研究中心I期2023-05 启动
  8. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05938920研究中心II期2023-06 启动
  9. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05321069研究中心III期2022-10 启动
  10. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  11. Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)已完成NCT01170065研究中心II期2010-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年没有牵头肌萎缩侧索硬化症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 8 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Research Progress of CD4+T Cells-mediated Regulation of Neuroinflammation Involved in Neurodegenerative Diseases].2021Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

南京有 5 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07187440

    年龄 7 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科病理/检验科
中文论文(未计入)1
  1. [A case report of Fabry cardiomyopathy related to a de novo mutation of GLA gene].2025Zhonghua nei ke za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease正在招募NCT07187440研究中心2025-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 6 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Clinical analysis of 10 cases of pregnancy complicated with Behçet's disease].2025Zhonghua fu chan ke za zhi
早期论文(2016–2020 年)1
  1. Clinical Experience of Aortic Valve Surgery in Patients With Aortitis Disease.2019The heart surgery forum

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

南京有 8 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 3 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. The clinical application of single-sperm-based SNP haplotyping for PGD of osteogenesis imperfecta.2019Systems biology in reproductive medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南京有 10 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    分期
    III期
    开始
    2023-02
    登记号
    NCT05751967

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 6 家列出的医院为研究中心兰州、南京、天津、广州、成都、沈阳、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南京有 3 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年没有牵头遗传性大疱性表皮松解症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 3 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录
论文中的科室儿科
中文论文(未计入)1
  1. [A case of Neonatal generalized atrophic benign epidermolysis bullosa due to variants of COL17A1 gene].2024Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

南京有 2 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

南京鼓楼医院

Nanjing Drum Tower Hospital

南京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Comprehensive Cancer Centre of Drum Tower Hospital; Drum Tower Hospital; Affiliated Drum Tower Hospital of Nanjing University Medical School; Comprehensive Cancer Centre of Nanjing Drum Tower Hospital; Affiliated Drum Tower Hospital; Affiliated Drum Tower Hospital of Nanjing University; Nanjing Drum Tower Hospital Clinical College of Jiangsu University; Taikang Xianlin Drum Tower Hospital

提出更正下载数据